{"id":"48070caf-1992-516d-9039-635d35b1038b","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-nampt","predicate":"increases_in_recorded_comparison","statement":"The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"00d71455-caf0-5fd4-b704-68e2ca3e72cc","mechanism_event_label":"The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.","subject":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"object":{"id":"8272125c-0d87-5920-9dae-7409b797bbfa","slug":"nampt","display_name":"Human nicotinamide phosphoribosyltransferase / NAMPT","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"00d71455-caf0-5fd4-b704-68e2ca3e72cc","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-nampt-event","event_type":"experimental_observation","label":"The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.","description":"### api-human-combined-nampt\n\nThe combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.\nIndividual ingredient causality and enzyme flux were not isolated.\nModel and exposure: Human crossover trial; multicomponent preparation.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"Multicomponent preparation","sequence_order":0,"notes":""},{"entity":{"id":"8272125c-0d87-5920-9dae-7409b797bbfa","slug":"nampt","display_name":"Human nicotinamide phosphoribosyltransferase / NAMPT","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"b8e1bfa9-c412-5f35-97af-cfc722123d27","slug":"sirt1","display_name":"SIRT1","entity_type_key":"protein"},"role":"increased protein readout","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Multicomponent preparation\", \"comparator\": \"Study baseline comparison\", \"endpoint\": \"The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Human crossover trial; multicomponent preparation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-human-combined-nampt; Individual ingredient causality and enzyme flux were not isolated.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3b30692a-2d5a-5e0e-8789-1b21d743dd91","evidence_kind":"source_excerpt","locator":"Lines 516-522","start_line":516,"end_line":522,"excerpt":"### api-human-combined-nampt\n\nThe combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.\nIndividual ingredient causality and enzyme flux were not isolated.\nModel and exposure: Human crossover trial; multicomponent preparation.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Human crossover trial; multicomponent preparation.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}